Page 37 - 2021_06-Haematologica-web

CAR T cell therapies in multiple myeloma
(RRMM): update of the phase 1/2 EVOLVE study (NCT03430011). J Clin Oncol. 2020;38(15_suppl):8504.
57. Alsina M, Shah N, Raje NS, et al. Updated results from the phase I CRB-402 study of anti-Bcma CAR-T cell therapy bb21217 in patients with relapsed and refractory multi- ple myeloma: correlation of expansion and duration of response with T cell pheno- types. Blood. 2020;136 (Suppl 1):S25-26.
58.Kuramitsu S, Ohno M, Ohka F, et al. Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor vari- ant III by enhancing immune synapses. Cancer Gene Ther. 2015;22(10):487-495.
59. Wang X, Walter M, Urak R, et al. Lenalidomide enhances the function of CS1 chimeric antigen receptor-redirected T cells against multiple myeloma. Clin Cancer Res. 2018;24(1):106-119.
Front Immunol. 2020;11:1128.
71. Rafiq S, Hackett CS, Brentjens RJ.
Engineering strategies to overcome the cur- rent roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17(3):147-167.
72. Tan AHJ, Vinanica N, Campana D. Chimeric antigen receptor-T cells with cytokine neutralizing capacity. Blood Adv. 2020;4(7):1419-1431.
73. Gargett T, Brown MP.The inducible cas- pase-9 suicide gene system as a "safety switch" to limit on-target, off-tumor toxici- ties of chimeric antigen receptor T cells. Front Pharmacol. 2014;5:235.
74. Smith EL, Harrington K, Staehr M, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019;11(485):eaau7746.
75. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol. 2005;23(9):1126-1136.
76. Lam N, Trinklein ND, Buelow B, Patterson GH, Ojha N, Kochenderfer JN. Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains. Nat Commun. 2020;11(1): 283.
77. Kumar M, Keller B, Makalou N, Sutton RE. Systematic determination of the packaging limit of lentiviral vectors. Hum Gene Ther. 2001;12(15):1893-1905.
78. De Munter S, Ingels J, Goetgeluk G, et al. Nanobody based dual specific CARs. Int J Mol Sci. 2018;19(2):403.
79. Martyniszyn A, Krahl AC, Andre MC, Hombach AA, Abken H. CD20-CD19 bis- pecific CAR T cells for the treatment of B- cell malignancies. Hum Gene Ther. 2017;28(12):1147-1157.
80. Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 2018;8(10):1219-1226.
81. Hamieh M, Dobrin A, Cabriolu A, et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature. 2019;568(7750):112-116.
82. Hegde M, Mukherjee M, Grada Z, et al. Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape. J Clin Invest. 2016;126(8):3036- 3052.
83.Garfall AL, Cohen AD, Lacey SF, et al. Combination anti-Bcma and anti-CD19 CAR T cells as consolidation of response to prior therapy in multiple myeloma. Blood. 2019;134(supplement 1):1863.
(6):498-508.
87. Jiang H, Dong B, Gao L, et al. Clinical
results of a multicenter study of the first-in- human dual BCMA and CD19 targeted novel platform fast CAR-T cell therapy for patients with relapsed/refractory multiple myeloma. Blood. 2020;136(Suppl 1):S25- 26.
88. Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refracto- ry multiple myeloma. Blood. 2017;130 (8):974-981.
89. Wang X, Walter M, Urak R, et al. Lenalidomide enhances the function of CS1 chimeric antigen receptor-redirected T cells against multiple myeloma. Clin Cancer Res 2018;24(1):106–119.
90. Amor C, Feucht J, Leibold J, et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature. 2020;583(7814):127- 132.
91. Ciavarella S, Laurenzana A, De Summa S, et al. u-PAR expression in cancer associated fibroblast: new acquisitions in multiple myeloma progression. BMC Cancer. 2017; 17(1):215.
92. Wagner V, Gil J. T cells engineered to target senescence. Nature. 2020;583(7814):37-38.
93. Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. 'Off-the-shelf' allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19(3):185-199.
94. Cong L, Ran FA, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339(6121):819-823.
95. Sommer C, Boldajipour B, Kuo TC, et al. Preclinical evaluation of allogeneic CAR T cells targeting BCMA for the treatment of multiple myeloma. Mol Ther. 2019;27(6): 1126-1138.
96. Zhou X, Dotti G, Krance RA, et al. Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood. 2015;125(26):4103-4113.
97. Yakoub-Agha I, Chabannon C, Bader P, et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica. 2020;105 (2):297-316.
98. Hill JA, Li D, Hay KA, et al. Infectious com- plications of CD19-targeted chimeric anti- gen receptor-modified T-cell immunothera- py. Blood. 2018;131(1):121-130.
99. Ljungman P, Mikulska M, de la Camara R, et al. The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. Bone Marrow Transplant. 2020;55(11):2071-2076
100. Cher BP, Gan KY, Aziz MIA, et al. Cost util- ity analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lym- phoma from Singapore's healthcare system perspective. J Med Econ. 2020;23(11):1321- 1329.
60. Works M, Soni N, Hauskins C, et al. Anti- B-cell maturation antigen chimeric antigen receptor T cell function against multiple myeloma is enhanced in the presence of lenalidomide. Mol Cancer Ther. 2019;18(12):2246-2257.
61. Pont MJ, Hill T, Cole GO, et al. γ-Secretase inhibition increases efficacy of BCMA-spe- cific chimeric antigen receptor T cells in multiple myeloma. Blood. 2019;134(19): 1585-1597.
62. Garfall AL, Maus MV, Hwang WT, et al. Chimeric antigen receptor T cells against CD19 for multiple myeloma. N Engl J Med. 2015;373(11):1040-1047.
63. Yan Z, Cao J, Cheng H, et al. A combina- tion of humanised anti-CD19 and anti- BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol. 2019;6(10):e521-e529
64. Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625- 638.
65. Ragoonanan D, Khazal SJ, Abdel-Azim H, et al. Diagnosis, grading and management of toxicities from immunotherapies in chil- dren, adolescents and young adults with cancer. Nat Rev Clin Oncol. 2021;18(7): 435-453.
66. Pennisi M, Jain T, Santomasso BD, et al. Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. Blood Adv. 2020;4(4):676-686.
67. Wäsch R, Munder M, Marks R. Teaming up for CAR-T cell therapy. Haematologica. 2019;104(12):2335-2336.
68. Gagelmann N, Riecken K, Wolschke C, et al. Development of CAR-T cell therapies for multiple myeloma. Leukemia. 2020;34 (9):2317-2332.
69. Mikkilineni L, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for multi- ple myeloma. Blood. 2017;130(24):2594- 2602.
70. García-Guerrero E, Sierro-Martínez B, Pérez-Simón JA. Overcoming chimeric antigen receptor (CAR) modified T-cell therapy limitations in multiple myeloma.
84.
85.
Shi X, Yan L, Shang J, et al. Tandom autol- ogous transplantation and combined infu- sion of CD19 and Bcma-specific chimeric antigen receptor T cells for high risk MM: initial safety and efficacy report from a clin- ical pilot study. Blood. 2018;132(Suppl 1):S1009. LiC,MeiH,HuY,GuoT,LiuL,JiangH.A bispecific CAR-T cell therapy targeting Bcma and CD38 for relapsed/refractory multiple myeloma: updated results from a phase 1 dose-climbing trial. Blood. 2019;134(supplement 1):930.
86.Zah E, Lin MY, Silva-Benedict A, Jensen MC, Chen YY. T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malig- nant B cells. Cancer Immunol Res. 2016;4
haematologica | 2021; 106(8)
2065